Viekirax
AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences
The new site will expand research capabilities across immunology, neuroscience and oncology
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer
TNBC is the most aggressive type of breast cancer and has historically been difficult to treat
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations
Spanning four dimensions of skin health, the framework introduces 15 terms and definitions
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression
AbbVie reaches agreement for affordable prescription drugs with US government
The pharma company has also pledged a $100bn investment in US infrastructure over the next decade
Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance
Wettan has served at Gilead for over 14 years